公开(公告)号：US20170107284A1

公开(公告)日：2017-04-20

申请号：US15363986

申请日：2016-11-29

申请人： Compugen Ltd

发明人： Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi Yeshah ROSENBERG ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Merav BEIMAN ,  Ofer LEVY ,  Shira WALACH ,  Shirley SAMEACH- GREENWALD ,  Yaron KINAR ,  Zurit LEVINE ,  Gad S. COJOCARU ,  Sergey NEMZER

IPC分类号： C07K16/28 ,  G01N33/577 ,  G01N33/574 ,  C07K16/30 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K38/00 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3038 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N33/577 ,  G01N2333/47

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.

公开(公告)号：US20160347814A1

公开(公告)日：2016-12-01

申请号：US15066905

申请日：2016-03-10

申请人： Compugen Ltd.

发明人： Zurit LEVINE ,  Galit ROTMAN ,  Liat DASSA ,  Ofer LEVY ,  Gad S. COJOCARU ,  Amir TOPORIK ,  Yossef KLIGER ,  Ilan VAKNIN ,  Iris HECHT

IPC分类号： C07K14/705 ,  A61K45/06 ,  G01N33/574 ,  A61K39/39

CPC分类号： C07K14/705 ,  A61K31/675 ,  A61K38/00 ,  A61K39/39 ,  A61K45/06 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  G01N33/564 ,  G01N33/569 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/4703 ,  G01N2333/705 ,  Y02A50/411 ,  Y02A50/423 ,  A61K2300/00

摘要： This invention relates to VSTM5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.

摘要翻译： 本发明涉及VSTM5蛋白质，其可溶性分子及其融合物，其是用于药物开发和治疗免疫相关疾病，免疫治疗，癌症治疗，感染性疾病和/或败血症的合适靶标。

公开(公告)号：US20180298109A1

公开(公告)日：2018-10-18

申请号：US15882240

申请日：2018-01-29

申请人： Compugen Ltd.

发明人： Anat COHEN-DAYAG ,  Merav BEIMAN ,  Liat DASSA ,  Marina BUBIS ,  Shirley SAMEACH GREENWALD ,  Dalit LANDESMAN-MILO ,  Cynthia KOIFMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Zurit LEVINE ,  Avi ROSENBERG ,  Galit ROTMAN ,  Eve MONTIA ,  Amit NOVIK ,  Amir TOPORIK ,  Shira WALACH

IPC分类号： C07K16/30 ,  G01N33/574 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61K31/7088 ,  G01N33/564 ,  C07K16/28 ,  C07K14/82 ,  C07K14/705 ,  C07K14/47 ,  C07K14/00 ,  A61K38/00

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

公开(公告)号：US20160272707A1

公开(公告)日：2016-09-22

申请号：US15021239

申请日：2014-09-11

申请人： COMPUGEN LTD.

发明人： Zurit LEVINE ,  Galit ROTMAN ,  Liat DASSA ,  Ofer LEVY ,  Gad S. COJOCARU ,  Amir TOPORIK ,  Yossef KLIGER ,  Andrew POW ,  Spencer LIANG

IPC分类号： C07K16/28 ,  A61K31/664 ,  C07K16/30 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06

CPC分类号： C07K16/28 ,  A61K31/664 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5154 ,  C07K14/705 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  G01N33/564 ,  G01N33/57492 ,  G01N2800/24 ,  G01N2800/26 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/416 ,  Y02A50/421 ,  Y02A50/466 ,  A61K31/675 ,  A61K2039/5152 ,  A61K38/1774

摘要： The present invention relates to VSTM5-specific antibodies, antibody fragments, and VSTM5 polypeptides, conjugates and compositions comprising same, for modulating (antagonizing or agonizing) one or more of the effects of VSTM5 expression on immunity. More specifically, the present invention relates to VSTM5-specific antibodies, antibody fragments, and VSTM5 polypeptides, conjugates and compositions comprising same for treating and aiding in the diagnosis of cancer, infectious diseases and immune related diseases, e.g., those associated with aberrant (higher or lower than normal) VSTM5 expression by diseased and/or immune cells and/or aberrant (increased or reduced) VSTM5-mediated effects on immunity.

摘要翻译： 本发明涉及VSTM5特异性抗体，抗体片段和VSTM5多肽，包含其的组合物和组合物，用于调节（拮抗或激动）VSTM5表达对免疫力的一种或多种作用。 更具体地，本发明涉及VSTM5特异性抗体，抗体片段和VSTM5多肽，包含其的组合物和组合物，用于治疗和辅助诊断癌症，感染性疾病和免疫相关疾病，例如与异常（更高 或低于正常）VSTM5表达通过患病和/或免疫细胞和/或异常（增加或减少）VSTM5介导的免疫作用。

公开(公告)号：US20140255411A1

公开(公告)日：2014-09-11

申请号：US13845420

申请日：2013-03-18

申请人： Compugen Ltd.

发明人： Zurit LEVINE ,  Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi ROSENBERG ,  Cynthia KOIFMAN ,  Dalit LANDESMAN-MILO ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Marina BUBIS ,  Merav BEIMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Shira WALACH ,  Shirley SAMEACH- GREENWALD ,  Tania PERGAM ,  Yaron KINAR

IPC分类号： C07K16/30 ,  A61N5/10 ,  A61K39/39 ,  G01N33/574 ,  A61K47/48 ,  A61K39/395

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及发现VSIG1及其变体FXYD3及其变体ILDR1及其变体，LOC253012及其变体，AI216611及其变体和C1ORF32及其变体a的细胞外结构域，其是免疫治疗癌症的合适靶标 治疗和药物开发。

公开(公告)号：US20200369769A1

公开(公告)日：2020-11-26

申请号：US16766224

申请日：2018-11-28

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft ,  Compugen LTD.

发明人： Lars RÖSE ,  Uwe GRITZAN ,  Julia HÜTTER ,  Spencer LIANG ,  Andrew POW ,  John HUNTER ,  Ofer LEVY ,  Ilan VAKNIN

IPC分类号： C07K16/28 ,  A61K31/337 ,  A61K31/713 ,  A61P35/00

摘要： The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

公开(公告)号：US20180305451A1

公开(公告)日：2018-10-25

申请号：US15580723

申请日：2016-07-13

申请人： COMPUGEN LTD.

发明人： Yosef DICKEN ,  Liat DASSA ,  Amit NOVIK ,  Amir TOPORIK ,  Gad COJOCARU ,  Yossef KLIGER ,  Yair BENITA ,  Ofer LEVY ,  Ilan VAKNIN ,  Arthur MACHLENKIN ,  Iris HECHT ,  Jungmin KIM ,  Andrew POW ,  Andrew W DRAKE

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  A61K31/513 ,  C07K14/705

CPC分类号： C07K16/2803 ,  A61K31/513 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/572 ,  A61P35/00 ,  C07K14/70503 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

摘要： According to at least some embodiments of the present invention is directed to anti-HIDE1 antibodies and polypeptides and methods of using same.

公开(公告)号：US20140255389A1

公开(公告)日：2014-09-11

申请号：US13904028

申请日：2013-05-29

申请人： Compugen Ltd.

发明人： Anat COHEN-DAYAG ,  Merav BEIMAN ,  Liat DASSA ,  Marina BUBIS ,  Shirley SAMEACH- GREENWALD ,  Dalit LANDESMAN-MILO ,  Cynthia KOIFMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Zurit LEVINE ,  Avi ROSENBERG ,  Galit ROTMAN ,  Eve MONTIA ,  Amit NOVIK ,  Amir TOPORIK ,  Shira WALACH

IPC分类号： C07K14/705 ,  A61K39/00 ,  G01N33/564 ,  A61K45/06 ,  G01N33/574 ,  C07K16/28 ,  A61K39/395

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及VSIG1及其变体FXYD3及其变体ILDR1及其变体，LOC253012及其变体，AI216611及其变体和作为免疫治疗，癌症治疗的合适靶标的C1ORF32及其变体的细胞外结构域的发现 ，药物开发。

公开(公告)号：US20140220011A1

公开(公告)日：2014-08-07

申请号：US13767891

申请日：2013-02-15

申请人： Compugen Ltd.

发明人： Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi Yeshah ROSENBERG ,  Cynthia KOIFMAN ,  Dalit LANDESMAN-MILO ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Marina BUBIS ,  Merav BEIMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Shirley SAMEACH-GREENWALD ,  Zurit LEVINE ,  Shira WALACH

IPC分类号： C07K14/00 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, ClORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and ClORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，ClORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及VSIG1及其变体FXYD3及其变体ILDR1及其变体，LOC253012及其变体，AI216611及其变体以及作为免疫治疗，癌症治疗的合适靶标的ClORF32及其变体的细胞外结构域的发现 ，药物开发。

公开(公告)号：US20130315819A1

公开(公告)日：2013-11-28

申请号：US13904039

申请日：2013-05-29

申请人： Compugen Ltd.

发明人： Amir TOPORIK ,  Anat COHEN-DAYAG ,  Avi Yeshah ROSENBERG ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Meirav BEIMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Shira WALACH ,  Shirley SAMEACH- GREENWALD ,  Yaron KINAR ,  Zurit LEVINE

IPC分类号： A61K39/395

CPC分类号： A61K39/3955 ,  C07K14/47 ,  C07K16/28 ,  C07K16/2887 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/34

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对KIAA0746，CD20或CD55抗原的治疗性抗体，其在癌症和特异性血细胞中差异表达，以及诊断和治疗用途。 本发明还涉及KIAA0746及其变体​​CD20及其变体CD55及其变体的细胞外结构域的发现，其是免疫治疗，癌症治疗，炎性，过敏性和自身免疫性疾病的治疗以及药物开发的合适靶标。